Melior is using theraTRACE to both build an internal pipeline of development candidates as well as sharing this capability with pharmaceutical and biotechnology company partners.
Andrew Reaume, president and CEO of Melior, said: “Our agreement represents a significant opportunity for Melior to deliver value to AstraZeneca through the application of our unique and innovative in vivo testing platform. We look forward to a productive collaboration.”